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This study examined the pharmacokinetics of sirolimus in pediatric allogeneic blood and marrow trans-
plantation (BMT) recipients in the presence and absence of concomitant ﬂuconazole. Forty pediatric BMT
recipients received a daily oral dose of sirolimus and a continuous i.v. infusion of tacrolimus for graft-versus-
host disease prophylaxis. Fluconazole was administered i.v. to 19 patients and orally to 6 patients. Full
pharmacokinetic proﬁles of sirolimus within a single dosing interval were collected. Whole-blood sirolimus
concentrations were measured by HPLC/mass spectrometry. Noncompartmental analysis was performed
using WinNonlin. Nonlinear mixed-effects pharmacokinetic models were developed using NONMEM
following standard procedures. The mean  SD sirolimus trough level before the dose (C0) was 8.0  4.6
ng/mL (range, 1.8-21.6 ng/mL). The peak concentration was 19.9  11.8 ng/mL (range, 3.9-46.1 ng/mL), and the
trough level 24 hours later (C24) was 9.1  5.3 ng/mL (range, 1.0-19.1 ng/mL). The terminal disposition half-
life (T1/2) was 24.5  11.2 hours (range, 5.8-53.2 hours), and the area under the concentration-versus-time
curve (AUC0-24) was 401.1  316.3 ng$h/mL (range, 20.7-1332.3 ng$h/mL). In patients at steady state,
C0 and C24 were closely correlated (R2 ¼ 0.77) with a slope of 0.99, indicating the achievement of steady state.
C24 was 1.7-fold greater (P ¼ .036) and AUC0-24 was 2-fold greater (P ¼ .012) in Caucasian patients (n ¼ 22)
compared with Hispanic patients (n ¼ 9). The average apparent oral clearance was 3-fold greater (P ¼ .001)
and the apparent oral volume of distribution was 2-fold greater (P ¼ .018) in patients age 12 years compared
with those age >12 years. C24 was signiﬁcantly lower in patients (n ¼ 10) who developed grade III-IV aGVHD
(n ¼ 10) than in those with grade 0-II aGVHD (n ¼ 22) (6.1  2.9 ng/mL versus 9.4  5.5 ng/mL; P ¼ .044).
Dose-normalized sirolimus trough concentrations were signiﬁcantly higher in patients receiving concomitant
ﬂuconazole therapy compared with those not receiving ﬂuconazole (C0: 3.9  2.5 versus 2.4  1.5 ng/mL/mg,
P ¼ .030; C24: 4.8  3.3 versus 2.5  1.7 ng/mL/mg, P ¼ .018). This pharmacokinetic study of sirolimus in
pediatric patients documents a large interindividual variability in the exposure of sirolimus. Steady-state
trough blood concentrations were correlated with drug exposure. Trough concentrations were higher with
a concomitant use of ﬂuconazole and were higher in Caucasian patients than in Hispanic patients. Oral
clearance was greater in children age12 years than in older children and adolescents. With therapeutic drug
monitoring, the majority (79%) of sirolimus trough levels could be maintained within the target range (3-12
ng/mL). This study provides a rationale and support for dose adjustments of sirolimus based on steady-state
blood concentrations aimed at achieving a target concentration to minimize toxicity and maximize thera-
peutic beneﬁts in pediatric BMT recipients.
 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.INTRODUCTION T cell proliferation, a mechanism of action distinct from
Sirolimus (or rapamycin) is a macrocyclic antibiotic with
immunosuppressive and antineoplastic properties. It binds
to the FK-binding protein 12 and inhibits the mammalian
target of rapamycin, resulting in cell cycle arrest at the G1/S
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In solid organ transplant recipients, sirolimus and tacro-
limus have been used in combination owing to their syner-
gistic immunosuppressive effects and nonoverlapping
toxicity proﬁles. In blood and marrow transplantation (BMT)
recipients, sirolimus has been used for the prevention and
treatment of graft-versus-host disease (GVHD) [1,2]. In adult
BMT recipients receiving myeloablative conditioning,
a prophylactic regimen including sirolimus and tacrolimus
was associated with lower rates of acute GVHD (aGVHD) and
less mucositis compared with a regimen including tacroli-
mus and methotrexate [2].
Sirolimus is available only as an oral formulation and has
low bioavailability owing to countertransport into the
gut lumen by the p-glycoprotein (P-gp) multidrug efﬂuxTransplantation. Published by Elsevier Inc. All rights reserved.
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wall and the liver. Numerous factors can inﬂuence the
absorption and bioavailability of sirolimus in BMT recipients,
including conditioning-related nausea and emesis, mucositis
and intestinal GVHD, functional gene polymorphisms in
metabolic enzymes, and the concurrent use of CYP450
inhibitors, such as azole antifungal drugs [3,4].
Fluconazole is widely used for Candida prophylaxis in
patients undergoing BMT who receive cytotoxic chemo-
radiotherapy. The literature on interactions between ﬂuco-
nazole and sirolimus is scant, but such interactions have
been implied largely from 2 case reports and based on
observed interactions between other azoles and calcineurin
inhibitors [5-7].
Because of its long half-life, sirolimus is administered
once a day to achieve the target therapeutic concentrations.
Pharmacokinetic studies have shown a shorter half-life in
pediatric solid organ transplant recipients compared with
healthy controls and adult transplant recipients [8,9].
Although the pharmacokinetics of sirolimus have been well
studied in solid organ transplant recipients, the drug has not
yet been thoroughly evaluated in pediatric BMT recipients.
We recently reported clinical ﬁndings from a multi-
institutional pilot trial of the addition of sirolimus to
tacrolimus-methotrexate GVHD prophylaxis in children
undergoing allogeneic BMT [10]. The objectives of the present
study were to characterize the pharmacokinetics of sirolimus
in pediatric BMT recipients with and without concomitant
use of ﬂuconazole, and to identify factors signiﬁcantly asso-
ciated with variability in these pharmacokinetics.
PATIENTS AND METHODS
Study Subjects
Between September 2005 and June 2007, 4 pediatric transplant centers
(Children’s Hospital of Philadelphia; Methodist Children’s Hospital of South
Texas, San Antonio; Primary Children’s Medical Center, Salt Lake City; and
Children’s Hospital of Pittsburgh) participated in a prospective phase II trial
of sirolimus-based GVHD prophylaxis. The trial was approved by the Insti-
tutional Review Boards of the 4 institutions. Informed consent was obtained
from guardians and assent or consent was obtained from patients in
accordance with the Declaration of Helsinki.
Conditioning Regimen and GVHD Prophylaxis
All patients underwent BMT for high-risk acute lymphoblastic leukemia.
The preparative regimen consisted of 1200 cGy fractionated total body
irradiation, 10 mg/kg thiotepa, and 120 mg/kg cyclophosphamide. GVHD
prophylaxis consisted of sirolimus, tacrolimus, and methotrexate. Sirolimus
was given without a loading dose, at a starting dose of 2.5 mg/m2/day and
with target trough levels of 3-12 ng/mL. Tacrolimus was started on day 2 as
a continuous infusion at a starting dose of 0.03 mg/kg/day and with a target
concentration of 5-10 ng/mL. Methotrexate was given i.v. at a dose of
5 mg/m2 for 4 or 5 doses.
Blood Sampling and Analytical Assays
To characterize the pharmacokinetics of sirolimus, multiple serial blood
samples (0.5-1 mL) were collected within a single oral dosing interval from
each patient. Blood sampling was performed immediately before (0 hour)
and at 0.5, 1, 2, 4, 6, 12, and 24 hours after administration of a minimum of
4 oral doses to allow achievement of steady state. Additional trough samples
were also collected from each patient for therapeutic drug monitoring as
part of clinical care at each study site. Whole-blood concentrations of siro-
limus were measured using modiﬁcation of a validated HPLC/mass spec-
trometry (MS) method [11]. The coefﬁcient of variation of the assay was
<10% of all concentrations tested.
Noncompartmental Pharmacokinetic Analysis
The difference in trough concentrations before oral dosing (C0) and at
24 hours after oral dosing (C24) was tested using a paired 2-tailed Student
t test to conﬁrm the attainment of steady state. The area under the
concentration-versus-time curve speciﬁc for the dose evaluated (AUC0-24)
was calculated using the trapezoid rule. Various pharmacokineticparameters were calculated by noncompartmental analysis using Win-
Nonlin version 4.1 (Pharsight, Mountain View, CA). The terminal disposition
rate constant (lz) and terminal disposition half-life (t1/2) were derived from
data points during the terminal disposition phase, when at least 3 data
points were available. Projected trough concentrations (C24) were used if the
observed C24 value was missing. Statistical comparisons of different
parameters were made using a paired 2-tailed Student t test with R. A
P value of <.05 was considered statistically signiﬁcant.
Covariate Relationship Exploration
Covariate relationships were ﬁrst visually evaluated by plotting an
empirical Bayesian estimate against covariates. Covariate effects were
then tested by incorporating covariates into the base model (without
a covariate) one at a time using at least 13 approaches to associate the
covariate with the parameter. Different cutoff values for the covariates
were tested as well. A covariate was considered signiﬁcant and a cutoff
value was considered optimal if all of the following criteria were met: (1)
a decrease in the objective function value of 6.63 for 1 degree of freedom
(P < .01), (2) no signiﬁcant trend in empirical Bayesian estimates versus
covariate plots, (3) improved goodness-of-ﬁt, (4) reduced interindividual
variability, and (5) clinical plausibility of incorporating the covariate. The
ﬁnal model was obtained using the standard forward addition and reverse
removal approach with the same criteria. The adequacy of ﬁtting was
examined by plotting predicted versus observed concentrations (good-
ness of ﬁt) versus time proﬁles and weighted residuals versus predicted
concentrations.
Population Pharmacokinetic Analysis
A nonlinear mixed-effects pharmacokinetic model (base model) was
developed using NONMEM 7 (GloboMax, Hanover, MD) and a ﬁrst-order
conditional estimation method with interaction. Correlations among phar-
macokinetic parameters were also incorporated and estimated. One-
compartment and 2-compartment models were tested with ﬁrst-order
and zero-order elimination. Interindividual variability was described using
the exponential model
Pij ¼ TV

Pj
 ehij ;
where Pij is the ith individual’s estimate of the jth pharmacokinetic
parameter, TV(Pj) is the typical value of the jth pharmacokinetic parameter,
and hij is a random variable for the ith individual and the jth pharmacoki-
netic parameter distributed with mean 0 and variance uj2. Various residual
variability models were tested, including the following:
 Additive error model: Cobs ¼ Cpred þ ε
 Proportional error model: Cobs ¼ Cpred  ð1þ εÞ
 Combined error model: Cobs ¼ Cpred  ð1þ εÞ þ ε0
 Exponential error model: Cobs ¼ Cpred  eε:
Here Cobs and Cpred are the observed and predicted concentrations, and ε
and ε0 are normal random variables with mean 0 and variance of d2 and d02,
respectively. To estimate clearance normalized to bodyweight, an additional
base model was also developed with the clearance coded as
CLi ¼ WTi  TVðCLÞ  ehi:
RESULTS
Patient and Transplant Characteristics
Pharmacokinetic proﬁles of sirolimus were evaluated in
40 pediatric BMT recipients. Patient and transplantation
characteristics are summarized in Table 1. Sirolimus was
initiated on day 0 in 38 patients, on day þ1 in 1 patient, and
on dayþ2 in 1 patient. The mean oral sirolimus dose was 2.5
 1.0 mg (range, 1-5 mg) once daily on the day of the study.
The tacrolimus dose ranged from 0.00 to 0.066 mg/kg/day
given as a continuous i.v. infusion. Blood samples for siroli-
mus pharmacokinetics were collected after a median of
6 doses (range, 4-10 doses). Twenty-ﬁve of 40 patients
received ﬂuconazole prophylaxis. Collectively, for these
40 patients, 232 of 259 sirolimus doses (89.6%) were the
same as the ﬁrst dose during the pharmacokenetic study.
Table 1
Patient and Transplant Characteristics
Characteristic Value
Number of patients 40
Age, years, median  SD (range) 10.1  5 (4-22)
Weight, kg, median  SD (range) 34.8  19.0 (13.2-84.3)
Sex, n (%)
Male 27 (67)
Female 13 (33)
Race/ethnicity, n (%)
Caucasian 27 (67)
Hispanic 11 (28)
African American 1 (2.5)
Asian 1 (2.5)
Transplant type, n (%)
Related donor 16 (40)
Unrelated donor 24 (60)
Type of donor graft, n (%)*
Bone marrow 18 (45)
Umbilical cord blood 23 (58)
Peripheral blood 1 (2)
* Two patients received both bone marrow and cord blood.
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daily before pharmacokenetic samples were collected.
Sirolimus doses were decreased in the other 10 patients
based on clinical trough levels; all of these patients were on
ﬂuconazole. None of the 15 patients who did not receive
ﬂuconazole received another azole; 13 patients received low-
dose amphotericin-B, and 2 received micafungin for anti-
fungal prophylaxis.
Pharmacokinetic Analysis of Sirolimus
The observed blood concentrations of sirolimus (C0)
during the dosing interval and the mean concentrations of
sirolimus in all the study subjects are shown in Figure 1. The
patients were divided into 4 group: those not receiving ﬂu-
conazole, those receiving concomitant i.v. ﬂuconazole, those
receiving concomitant oral ﬂuconazole, and those who
vomited after sirolimus administration. There was a wide
interindividual variation in the whole-blood sirolimus
concentrations as shown in the left panel. Population mean
proﬁles for patients are shown in the right panel. Most
sirolimus whole-blood concentrations (79%) were main-
tained within the target range of 3-12 ng/mL, whereas 9% of40 Oral Fluconazole
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Figure 1. Whole-blood 0 h concentrations of sirolimus for all subjects (n ¼ 40) over a
ﬂuconazole, concomitant i.v. ﬂuconazole, concomitant oral ﬂuconazole, and vomitingsirolimus whole-blood concentrations were <3 ng/mL and
12% were >12 ng/mL.
Noncompartmental pharmacokinetic analysis was per-
formed on 33 patients after excluding 5 patients with
extremely atypical proﬁles who had fewer than 3 data
points during the terminal disposition phase and 2 others
who vomited after the sirolimus dose on the study day. As
shown in Table 2, there was considerable interpatient vari-
ation in the pharmacokinetic parameters for sirolimus. The
sirolimus concentrations (mean  SD) were as follows:
trough level before the dose (C0), 8.0  4.6 ng/mL; peak
concentration (Cmax), 19.9  11.8 ng/mL; and trough level 24
hours later (C24), 9.1  5.3 ng/mL. The difference between
the trough concentrations (C24 - C0)/C24 averaged 10.3% and
was not signiﬁcantly greater than 0 (P ¼ .75). The C0 and C24
were moderately correlated with AUC0-24 (0.52 and 0.51,
respectively). In patients at a steady state (n ¼ 22),
excluding those with prolonged absorption, C0 and C24
correlated well (R2 ¼ 0.77), with a slope of 0.99, indicating
achievement of a steady state. The time to maximum
concentration was 3.3  1.6 hours, terminal disposition half-
life (t1/2) was 24.5  11.2 hours, AUC0-24 was 401.1  316.3
ng$h/mL, apparent oral clearance (Cl/F) was 0.19  0.18 L/h/
kg of body weight, and apparent oral volume of distribution
(Vd/F) was 5.78  5.70 L/kg.
On covariate analysis, the average Cl/F of sirolimus was
3-fold greater and Vd/f was 2-fold greater in patients age12
years than in those age >12 years. The mean sirolimus t1/2
was 21.8 hours in patients age 12 years and 29.2 hours in
those age >12 years (Figure 2). The dose-normalized siroli-
mus C24 was 1.7-fold greater and the dose-normalized AUC0-
24 was 2-fold greater in Caucasian patients (n ¼ 22)
compared with Hispanic patients (n ¼ 9) (Figure 3). There
was no signiﬁcant difference in mean age between the
Caucasian and Hispanic patient groups (11.5  5.2 years
versus 10.2  5.9 years; P ¼ .59). Trough sirolimus concen-
trations (C24) were signiﬁcantly lower in patients who
developed grade III-IV aGVHD (n ¼ 10) than in those with
grade 0-II aGVHD (n ¼ 22) (6.11  2.89 ng/mL versus 9.42 
5.52 ng/mL; P ¼ .044). None of the other variables evaluated
in the study (sex, body weight, hemoglobin, bilirubin,
aspartate aminotransferase, alanine aminotransferase,
albumin, blood urea nitrogen, and serum creatinine) were27
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Table 2
Noncompartmental Analysis of Sirolimus
All (n ¼ 33) No Fluconazole (n ¼ 11) i.v. Fluconazole (n ¼ 16) Oral Fluconazole (n ¼ 6)
Half-life, h 24.5  11.2 (5.8w53.2) 26.6  14.6 (5.8w53.2) 23.7  9.2 (9.9w44.3) 22.8  10.0 (8.6w39.0)
Tmax, h 3.3  1.6 (1.0w6.3) 3.2  1.0 (2.0w4.2) 3.4  1.9 (1.0w6.3) 3.4  1.9 (1.0w6.1)
Cmax, ng/mL 19.9  11.8 (3.9w46.1) 21.3  15.4 (4.1w44.5) 19.4  11.0 (3.9w46.1) 18.7  7.0 (12.1w32.0)
Cl/F, L/h 5.8  4.5 (1.6w22.7) 5.7  3.0 (2.2w11.1) 5.7  5.2 (1.6w22.7) 6.3  5.7 (1.6w17.2)
Cl/F, L/h/kg 0.19  0.18 (0.03w0.86) 0.19  0.13 (0.03w0.45) 0.19  0.22 (0.03w0.86) 0.19  0.19 (0.05w0.57)
Vd/F, L 184.6  128.1 (38.6w534.7) 201.3  121.3 (39.7w460.1) 182.7  151.7 (38.6w534.7) 159.2  71.6 (57.7w249.1)
Vd/F, L/kg 5.78  5.70 (1.44w25.23) 6.64  5.31 (1.48w16.56) 5.75  6.95 (1.44w25.23) 4.31  1.66 (2.61w7.03)
AUC, ng$h/mL 401.1  316.3 (20.7w1332.3) 450.4  367.2 (84.5w1332.3) 398.9  236.9 (24.8w762.4) 323.5  413.5 (20.7w1146.0)
AUC, ng$h/mL/mg 170.7  134.7 (10.4w573) 147.4  88.8 (52.9w333.1) 203.2  122.9 (16.5w392.4) 139.3  214.8 (10.4w573)
Co, ng/mL 8.0  4.6 (1.8w21.6) 6.8  4.8 (1.8w16.5) 8.0  4.1 (3.7w21.6) 11.0  5.3 (5.6w17.4)
Co, ng/mL/mg 3.4  2.3 (0.7w10.8) 2.3  1.5 (0.7w5.5) 4.0  2.6 (1.8w10.8) 3.7  2.4 (1.8w7.8)
C24, ng/mL 9.1  5.3 (1.0w19.1) 8.0  6.3 (1.0w18.9) 10.0  4.2 (4.6w19.1) 8.6  6.5 (1.0w16.8)
C24, ng/mL/mg 4.1  3.1 (0.2w12.1) 2.5  1.7 (0.2w6.3) 5.3  3.5 (1.5w12.1) 3.2  2.6 (0.3w6.8)
Fluconazole dose, mg* 201.0  93.8 (100w400) 188.9  78.4 (100w400) 237.5  132.0 (100w400)
Sirolimus dose, mg* 2.5  1.0 (1w5) 2.8  1.3 (1w5) 2.2  0.8 (1w4) 2.8  1.0 (2w4)
Sirolimus formulation, ny 24/7/7/2 9/2/4/0 10/5/3/1 5/0/0/1
Tmax indicates time to reach maximum concentration; Cmax, maximum concentration; Vd/F, apparent oral volume of distribution; Cl/F, apparent oral clearance;
AUC, Area under the concentration-vs-time curve speciﬁc for the dose evaluated; Co, trough concentration prior to oral dosing; C24, trough concentration at 24
hours after oral dosing.
Values are expressed as mean  SD (range) unless indicated otherwise.
* Fluconazole or sirolimus dose administered on the day of the sirolimus pharmacokinetic study.
y Values are number of patients for tablet/suspension/both/unknown.
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sirolimus (data not shown).Effect of Concomitant Fluconazole on Pharmacokinetics
of Sirolimus
Twenty-ﬁve patients received ﬂuconazole prophylaxis at
a mean dose of 201  93.8 mg (5.4  1.3 mg/kg) once daily,
starting on day 6 (range, day 16 to day 5). Fluconazole was
administered i.v. in 16 patients and orally in 6 patients.
Sirolimus doses were not signiﬁcantly different in pediatric
BMT recipients with concomitant ﬂuconazole and those
without concomitant ﬂuconazole (Table 2). Sirolimus trough
concentrations were signiﬁcantly higher in patients
receiving ﬂuconazole compared with those not receiving
ﬂuconazole (Figure 4). Dose-normalized sirolimus C0 values
were 3.93  2.5 ng/mL/mg in patients receiving concomitant
ﬂuconazole versus 2.35  1.5 ng/mL/mg in those not
receiving concomitant ﬂuconazole (P ¼ .0299), and corre-
sponding C24 values were 4.8  3.34 ng/mL/mg versus 2.5 
1.7 ng/mL/mg (P ¼ .0177).
The population pharmacokinetic analysis included a total
of 333 sirolimus concentrations from 37 patients. Two
patients who vomited and 1 patient with extreme atypical
pharmacokinetic proﬁles were excluded, because it was notFigure 2. Standard box-and-whisker plots showing Cl/F, Vd/F, and t1/2 of sirolimus in
values.possible to calculate any pharmacokinetic parameters from
these patients. A 2-compartment model with ﬁrst-order
absorption and elimination adequately described the data.
The population pharmacokinetic estimates are shown in
Table 3. These estimates are consistent with the results from
the noncompartmental analysis. Interindividual variability
was estimated for clearance (78%); volume of distribution of
central compartment, Vc (91%); and absorption rate
constant, ka (63%). The residual variability was best
described using the following combined error model:
Cobs ¼ Cpred  ð1þ εÞ þ ε0 :
The proportional and additive residual variabilities were
0.21 and 0.84 ng/mL, respectively. The additive error esti-
mate was lower than the lowest limit of quantiﬁcation of the
assay (2 ng/mL). Individual predictions agreed well with our
observations. Weighted residuals were approximately nor-
mally distributed. None of the variables evaluated in this
study was signiﬁcantly associated with any sirolimus phar-
macokenetic parameters.DISCUSSION
Previous studies in BMT recipients have examined rela-
tionship of sirolimus dose and drug levels with clinicalthe 12-year and >12-year age groups. Solid horizontal lines represent median
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Figure 3. Standard box-and-whisker plots showing sirolimus trough concentrations and AUC0-24 in Caucasian and Hispanic patients. Solid horizontal lines represent
median values.
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syndrome, GVHD and survival [1,2,12,13]. Although the
pharmacokinetics of sirolimus have been well characterized
in adult and pediatric organ transplant recipients [9,14,15], to
our knowledge this is the ﬁrst systematic study of sirolimus
pharmacokinetics in a BMT population. Here we report the
results of sirolimus pharmacokinetics in pediatric patients
treated uniformly on a common total body irradiationebased
conditioning regimen and sirolimus and tacrolimusebased
GVHD prophylaxis.
The mean AUC0-24 of sirolimus in this study was 401.1 
316.3 ng$h/mL, nearly double the values previously reported
in adult kidney transplant recipients (173  50 ng$h/mL),
pediatric liver transplant recipients (168.3  86.5 ng$h/mL),
and pediatric small bowel transplant recipients (177.4  72.1
ng$h/mL) [9,14]. More important, the corresponding Cl/F of
sirolimus was one-half the value reported in pediatric liver
and small intestinal transplant recipients. The Cl/F in our
patients appears to be closer to the Cl/F reported in pediatric
kidney transplant recipients on calcineurin inhibitor therapy
[15]. The lower Cl/F of sirolimus in our patient population
may reﬂect the functional status of the liver (ie, less ability to
metabolize the drug) or greater bioavailability of the drug
(owing to decreased presystemic metabolism) in this group
of patients. Given the lack of an i.v. formulation of sirolimus
at this point, it is not possible to distinguish between these
2 factors. Of note, the pharmacokinetic study was performed
in these patients early in the course of a myeloablative
regimen, when the effects of preparative regimens on liver
and intestine are signiﬁcant. It is possible that with time andWith Fluconazole Without Fluconazole
Figure 4. Standard box-and-whisker plots showing dose-normalized trough sirolim
therapy and those not receiving ﬂuconazole. Values are median and 95% CI. Solid hoafter a conditioning regimen, the Cl/F may increase and the
AUC0-24 may decrease in these patients relative to values
observed in solid organ transplant recipients. Another reason
for the lower Cl/F in our population may be related to the
routine use of steroids in solid organ transplant recipients,
leading to increased sirolimus metabolism and thus a lower
AUC0-24 in solid organ transplant recipients compared with
BMT recipients.
Trough blood concentrations of sirolimus were closely
correlated with AUC0-24 values in our pediatric BMT recipi-
ents (R2 ¼ 0.52 for all patients and R2 ¼ 0.77 when patients
with prolonged absorption were excluded). This ﬁnding is
consistent with the good correlations reported in pediatric
liver and intestinal transplant recipients (R2 ¼ 0.85) [9],
pediatric kidney transplant recipients on a calcineurin-free
protocol (R2 ¼ 0.84) [8], and pediatric kidney transplant
recipients on tacrolimus cotherapy (R2 ¼ 0.68) [15].
In the present study, mean sirolimus t1/2 was 24.5  11.2
hours, similar to the half-life reported in pediatric liver
transplant recipients (21.2  14.1 hours) and small bowel
transplant recipients (19.3  5.6 hours) who received siro-
limus and tacrolimus immunosuppression [9]. Shorter t1/2
(9.7 hours at 1 month posttransplantation and 10.8 hours at
3 months posttransplantation) have been reported in pedi-
atric renal transplant patients treated on an every-12-hour
schedule on a calcineurin inhibitor-free protocol [8]. In
contrast, longer t1/2 (mean values of 47-107 hours) after
a single dose of sirolimus have been reported in pediatric
patients with stable chronic renal failure undergoing dialysis
[16]. These long half-lives are comparable to the 57-63 hoursWith Fluconazole Without Fluconazole
us concentrations (C0 and C24) in patients receiving concomitant ﬂuconazole
rizontal lines represent median values.
Table 3
Population Pharmacokinetic Analysis
Variable Population Estimate
(Standard Error)
Clearance (Cl/F) 6.66  1.10 L/h or 0.17  0.03 L/h/kg
Volume of distribution
of central
compartment (Vc)
26.9  7.7 L
Volume of distribution
of peripheral
compartment (Vp)
630  171 L
Intercompartment
clearance (Q)
4.62  2.00 L/h
Absorption rate constant (ka) 0.0535  0.0104 h-1
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healthy volunteers after a single dose of sirolimus. The
shorter half-life of sirolimus observed in our patients is
consistent with the shorter half-lives of other drugs, such as
cyclosporine and tacrolimus, in pediatric transplant recipi-
ents compared with adult transplant recipients.
Age has been shown to impact the t1/2 and Cl/F of tacro-
limus and sirolimus. In this study, although themean t1/2 was
24 hours, the value was lower in patients age 12 years
compared with those age >12 years. The weight-normalized
Cl/F was also 3-fold greater in patients age 12 years
compared with those age >12 years. Schachter et al. [8] re-
ported a signiﬁcantly shorter terminal t1/2 in the younger age
group (6 years: 8.2 hours; range, 4.4-10.6 hours; >6 years:
12.6 hours, range, 4.7-95.2 hours; P < .05) in kidney trans-
plant recipients on a calcineurin inhibitor-free protocol. The
same group reported a higher apparent clearance of siroli-
mus in patients age 0-5 years with or without concomitant
calcineurin inhibitors [15]. Age-dependent changes in the
expression and activity of cytochrome CYP3A isoenzymes
and P-gp may contribute to the observed variation in siroli-
mus clearance. Because sirolimus is not available in an i.v.
formulation, it is not possible to estimate the contribution of
differences in clearance and the bioavailability of sirolimus to
the observed changes in sirolimus exposure in older and
younger pediatric patients. The mean t1/2 values seen in the
present study support the practice of once-daily dosing of
sirolimus in pediatric BMT recipients in general. Patients
with shorter half-livesmay require higher doses or every-12-
hour dosing of sirolimus to reach target sirolimus trough
concentrations. If the measured trough blood concentration
is below but closer to the target, then a simple increase in
dose may be appropriate; in cases where the trough
concentration is farther below the target, a dosage increase
and every-12-hour dosing may be more logical.
African-American renal allograft recipients have poorer
renal allograft survival and higher mortality compared with
Caucasian recipients [17]. Differences in bioavailability and
the systemic exposure of calcineurin inhibitors and
mammalian target of rapamycin inhibitors (sirolimus and
everolimus) may be key contributing factors to the observed
differences in posttransplantation outcomes. African
Americans are known to have a higher Cl/F and lower oral
bioavailability of sirolimus compared with Caucasians.
Hispanics also have been reported to have a lower bioavail-
ability of tacrolimus compared with Caucasians [18]. No
differences in pharmacokinetics for other drugs, including
nortriptyline, have been reported between Hispanics and
Caucasians [19]. In the present study, the dose-normalized
steady-state C24 concentration of sirolimus was 1.7-fold
greater (P ¼ .036) and the dose-normalized AUC0-24 was2-fold greater (P ¼ .012) in Caucasian patients (n ¼ 22)
compared with Hispanic patients (n ¼ 9). It is possible that
racial/ethnic variations in the pharmacokinetics of drugs
may depend on the enzyme studied and the substrate used.
Racial/ethnic differences may be related to various genetic
and nongenetic factors, including known genetic variations
that inﬂuence transporter/enzyme activity such genes as
CYP3A4, CYP3A5, and ABCB1 MDR1 [3]. Sirolimus is
a substrate for cytochrome P450 3A (3A4 and 3A5) and P-gp
enzymes in the gut and liver. The proportions of CYP3A5
functional alleles were signiﬁcantly higher in African Amer-
icans (81.4%) and Hispanics (43.1%) compared with Cauca-
sians (16.8%) [20]. Our study was not designed to address
whether the observed differences are related to the
frequency of CYP3A5 alleles among different racial/ethnic
groups. These ﬁndings of lower steady-state C24 and AUC0-24
values in Hispanic patients require validation in larger
independent cohorts.
In this study, the cumulative incidence of grade II-IV and
grade III-IV aGVHD at 180 days was 38% and 21%, respectively
[10]. The mean sirolimus C24 value was signiﬁcantly lower in
patients who developed grade III-IV aGVHD (n ¼ 10)
compared with those with grade 0-II aGVHD (n ¼ 22) (6.11 
2.89 ng/mL versus 9.42  5.52 ng/mL; P ¼ .044). Malard et al.
[21] reported a signiﬁcant association between low cyclo-
sporine levels in the ﬁrst 2 weeks posttransplantation and an
increased risk of grade III-IV aGVHD. Jacobson et al. [22] re-
ported a direct correlation between grade III-IV aGVHD and
tacrolimus clearance. It is not possible to distinguish whether
the low concentrations were related to lower bioavailability
because of GVHD or whether the lower concentrations in
these patients predisposed them to higher-grade GVHD.
Moreover, these “low” sirolimus levels are within the study’s
target range, and given the lack of serial samples and data at
the onset of GVHD, this ﬁnding should be considered
preliminary and needs to be tested in a larger independent
cohort before generalizable conclusions can be drawn.
As reported previously, 7 of the 63 subjects in the clinical
study developed veno-occlusive disease of liver and 3
developed thrombotic microangiopathy [10]. Given the
concerns about these toxicities, particularly when sirolimus
and tacrolimus are used together, it would be of interest to
examine the relationship between sirolimus exposure and
these outcomes. The present single-point pharmacokenetic
study did not collect sufﬁcient clinical drug level data on all
patients to allow such a correlative analysis.
Sirolimus trough concentrations were signiﬁcantly higher
in patients on concomitant ﬂuconazole than in those not on
concomitant ﬂuconazole (C0: 3.93  2.5 versus 2.35  1.47
ng/mL/mg [P ¼ .030]; C24: 4.8  3.34 versus 2.51  1.72
ng/mL/mg [P ¼ .018]). Sirolimus is metabolized extensively
by the CYP3A system in the liver and is a substrate of the P-gp
transporter system. Fluconazole is an inhibitor of CYP3A4
and P-gp, although it is the weakest in vitro inhibitor of
CYP3A4 compared with itraconazole, voriconazole, and
posaconazole [7,23]. More potent interactions have been
described with extended-spectrum azoles, voriconazole, and
posaconazole, and more drastic sirolimus dosage reductions
have been recommended [6,24]. The general recommenda-
tion is to reduce the sirolimus dose by nearly 33% when
concomitant ﬂuconazole treatment is necessary. To date,
there have only been 2 case reports of interaction between
sirolimus and ﬂuconazole [5,25]. Our ﬁnding of 1.7- to
1.9-fold greater sirolimus concentrations with the concomi-
tant use of ﬂuconazole is consistent with the predicted
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importance of closely monitoring sirolimus blood concen-
trations. Before the pharmacokenetic blood draws, 10 of
20 patients on ﬂuconazole therapy had their sirolimus dose
decreased based on sirolimus therapeutic drug monitoring,
compared with none of the patients without ﬂuconazole
therapy. This dose decrease introduced bias; the observed
impact of ﬂuconazole in this study might have been greater
had no dosage adjustments been made before the formal
pharmacokenetic analysis.
In conclusion, our ﬁndings in this study of pediatric BMT
recipients can be summarized as follows: (1) signiﬁcant
interindividual variability in the exposure of sirolimus and
in its pharmacokinetics; (2) reasonably good correlation
between trough sirolimus blood concentrations and drug
exposure (AUC0-24); (3) lower apparent clearance of siroli-
mus compared with that in solid organ transplantation
recipients, at least in the early post-BMT period; (4) higher
apparent clearance in younger patients than in older pedi-
atric patients; (5) higher blood concentrations of sirolimus
when administered concomitantly with ﬂuconazole; (6)
lower drug exposure in Hispanics than in Caucasians; and
(7) an inverse association between GVHD and trough
sirolimus concentrations. With therapeutic monitoring,
a majority (79%) of the patients receiving sirolimus were
maintained within the target therapeutic range (3-12
ng/mL). This study provides a rationale and support for
sirolimus dose adjustments based on steady-state blood
concentrations to achieve the target concentration to mini-
mize toxicity and maximize therapeutic beneﬁts in pediatric
BMT recipients.
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